{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:35:08Z","timestamp":1767144908697,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.clim.2019.01.006","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000}}],"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003398","name":"Shanxi Scholarship Council of China","doi-asserted-by":"publisher","award":["2014-7"],"award-info":[{"award-number":["2014-7"]}],"id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004509","name":"Health and Family Planning Commission of Guangdong Province","doi-asserted-by":"publisher","award":["201601112"],"award-info":[{"award-number":["201601112"]}],"id":[{"id":"10.13039\/501100004509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473577"],"award-info":[{"award-number":["81473577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clim.2019.01.006","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T02:06:49Z","timestamp":1547690809000},"page":"35-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["RETRACTED: Hydroxyfasudil alleviates demyelination through the inhibition of MOG antibody and microglia activation in cuprizone mouse model"],"prefix":"10.1016","volume":"201","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Xuan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Juan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-Zhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Guo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cun-Gen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2019.01.006_bb0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WCO.0b013e328346056f","article-title":"Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications","volume":"24","author":"Stadelmann","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.clim.2019.01.006_bb0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn917","article-title":"Why does remyelination fail in multiple sclerosis?","volume":"3","author":"Franklin","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.clim.2019.01.006_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2019.01.006_bb0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nrn2480","article-title":"Remyelination in the CNS: from biology to therapy","volume":"9","author":"Franklin","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.clim.2019.01.006_bb0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2019.01.006_bb0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14728214.2018.1463370","article-title":"Emerging drugs for primary progressive multiple sclerosis","volume":"23","author":"Narayan","year":"2018","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.clim.2019.01.006_bb0035","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ni1507","article-title":"Multiple sclerosis: a complicated picture of autoimmunity","volume":"8","author":"McFarland","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0040","first-page":"193","article-title":"Remyelination in experimental models of toxin-induced demyelination","volume":"318","author":"Blakemore","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0045","article-title":"Five decades of cuprizone, an updated model to replicate demyelinating diseases","author":"Vega-Riquer","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.clim.2019.01.006_bb0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cm.20472","article-title":"Rho-kinase\/ROCK: a key regulator of the cytoskeleton and cell polarity","volume":"67","author":"Amano","year":"2010","journal-title":"Cytoskeleton"},{"key":"10.1016\/j.clim.2019.01.006_bb0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10409238.2013.786671","article-title":"Rho-associated coiled-coil kinase (ROCK) signaling and disease","volume":"48","author":"Schofield","year":"2013","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.clim.2019.01.006_bb0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1006\/bbrc.1998.8446","article-title":"Domain- and site-specific phosphorylation of bovine NF-L by Rho-associated kinase","volume":"245","author":"Hashimoto","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.clim.2019.01.006_bb0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1046\/j.1471-4159.2003.02054.x","article-title":"Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase","volume":"87","author":"Amano","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.clim.2019.01.006_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2443.1998.00181.x","article-title":"Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase","volume":"3","author":"Amano","year":"1998","journal-title":"Genes Cells"},{"key":"10.1016\/j.clim.2019.01.006_bb0075","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1083\/jcb.141.7.1625","article-title":"Molecular dissection of Rho-associated protein kinase-regulated neurite remodeling in neuroblastoma N1E-115 cells","volume":"141","author":"Hirose","year":"1998","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.clim.2019.01.006_bb0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-med-051914-022120","article-title":"Rho kinases in autoimmune diseases","volume":"67","author":"Pernis","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.clim.2019.01.006_bb0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpharm.2016.04.046","article-title":"Neuroprotection against cerebral ischemia\/reperfusion injury by intravenous administration of liposomal fasudil","volume":"506","author":"Fukuta","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.clim.2019.01.006_bb0090","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/cns.12002","article-title":"Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect","volume":"18","author":"Hou","year":"2012","journal-title":"CNS. Neurosci. Ther."},{"key":"10.1016\/j.clim.2019.01.006_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1871527315666160711104719","article-title":"Multitarget therapeutic effect of Fasudil in APP\/PS1transgenic mice","volume":"16","author":"Yu","year":"2017","journal-title":"CNS. Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.clim.2019.01.006_bb0100","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1093\/brain\/aws254","article-title":"Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease","volume":"135","author":"Tonges","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.clim.2019.01.006_bb0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/glia.22601","article-title":"Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis","volume":"62","author":"Tonges","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.clim.2019.01.006_bb0110","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1471-4159.2010.06876.x","article-title":"Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice","volume":"114","author":"Ding","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.clim.2019.01.006_bb0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.mcn.2009.11.001","article-title":"Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia\/reoxygenation injury in mice","volume":"43","author":"Ding","year":"2010","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.clim.2019.01.006_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1471-4159.2007.04756.x","article-title":"Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo","volume":"103","author":"Lingor","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.clim.2019.01.006_bb0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1529-8027.2006.00091.x","article-title":"Rho-kinase inhibition enhances axonal regeneration after peripheral nerve injury","volume":"11","author":"Hiraga","year":"2006","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.clim.2019.01.006_bb0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s12017-015-8374-6","article-title":"Role of Rho kinase and Fasudil on synaptic plasticity in multiple sclerosis","volume":"17","author":"Chen","year":"2015","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.clim.2019.01.006_bb0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/glia.22278","article-title":"The development of a rat in vitro model of spinal cord injury demonstrating the additive effects of Rho and ROCK inhibitors on neurite outgrowth and myelination","volume":"60","author":"Boomkamp","year":"2012","journal-title":"Glia"},{"key":"10.1016\/j.clim.2019.01.006_bb0140","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/j.jns.2013.07.1511","article-title":"BG, Polarization of macrophages and T cells to anti-inflammation in EAE mice treated with Fasudil","volume":"333","author":"Ma","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2019.01.006_bb0145","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/aps.2014.68","article-title":"Fasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis","volume":"35","author":"Chen","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.clim.2019.01.006_bb0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2005.06.003","article-title":"Fasudil Ischemic Stroke Study Group: Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial","volume":"238","author":"Shibuya","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2019.01.006_bb0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2176\/nmc.48.241","article-title":"Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study","volume":"48","author":"Suzuki","year":"2008","journal-title":"Neurol. Med. Chir."},{"key":"10.1016\/j.clim.2019.01.006_bb0160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1254\/jphs.11075FP","article-title":"Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage","volume":"118","author":"Satoh","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.clim.2019.01.006_bb0165","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.neubiorev.2005.04.017","article-title":"Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on","volume":"29","author":"Carobrez","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.clim.2019.01.006_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.plefa.2011.04.022","article-title":"Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage","volume":"85","author":"Yoshikawa","year":"2011","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.clim.2019.01.006_bb0175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1037\/a0014477","article-title":"Behavioral and neurobiological changes in C57BL\/6 mice exposed to cuprizone","volume":"123","author":"Xu","year":"2009","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.clim.2019.01.006_bb0180","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12264-013-1369-0","article-title":"Locomotor activity and anxiety status, but not spatial working memory, are affected in mice after brief exposure to cuprizone","volume":"29","author":"Zhang","year":"2013","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.clim.2019.01.006_bb0185","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.it.2010.06.006","article-title":"PG, B cells and autoantibodies: complex roles in CNS injury","volume":"31","author":"Ankeny","year":"2010","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0190","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1523\/JNEUROSCI.6595-10.2011","article-title":"Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion","volume":"31","author":"VonDran","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clim.2019.01.006_bb0195","doi-asserted-by":"crossref","DOI":"10.1177\/1759091414566878","article-title":"Brain-derived neurotrophic factor deficiency restricts proliferation of oligodendrocyte progenitors following cuprizone-induced demyelination","volume":"7","author":"Tsiperson","year":"2015","journal-title":"ASN. Neuro."},{"key":"10.1016\/j.clim.2019.01.006_bb0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"HP, Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.clim.2019.01.006_bb0205","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/jnr.23997","article-title":"Ultrastructural abnormalities and loss of myelinated fibers in the corpus callosum of demyelinated mice induced by cuprizone","volume":"95","author":"Xiu","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.clim.2019.01.006_bb0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12974-016-0682-8","article-title":"Interaction between interleukin-1\u03b2 and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis","volume":"13","author":"Gentile","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.clim.2019.01.006_bb0215","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/acer.13109","article-title":"Involvement of the hippocampus in binge ethanol-induced spleen atrophy in adolescent rats","volume":"40","author":"Liu","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.clim.2019.01.006_bb0220","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.4049\/jimmunol.176.11.6523","article-title":"Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages","volume":"176","author":"Offner","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0225","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11481-012-9406-8","article-title":"A transient decrease in spleen size following stroke corresponds to splenocyte release into systemic circulation","volume":"7","author":"Seifert","year":"2012","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.clim.2019.01.006_bb0230","first-page":"81","article-title":"Morphological changes of the thymus and spleen with acute experimental allergic encephalomyelitis (EAE) in Lewis rats","volume":"38","author":"Hara","year":"1986","journal-title":"No To Shinkei"},{"key":"10.1016\/j.clim.2019.01.006_bb0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00001756-200402090-00029","article-title":"Lateralization in autonomic dysfunction in ischemic stroke involving the insular cortex","volume":"15","author":"Meyer","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.clim.2019.01.006_bb0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.expneurol.2009.03.044","article-title":"Blockade of adrenoreceptors inhibits the splenic response to stroke","volume":"218","author":"Ajmo","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.clim.2019.01.006_bb0245","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.immuni.2017.02.015","article-title":"Brain ischemia suppresses immunity in the periphery and brain via different neurogenic innervations","volume":"46","author":"Liu","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2019.01.006_bb0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/toxsci\/kfv232","article-title":"Transcriptional profiling of dibenzo[def,p]chrysene-induced spleen atrophy provides mechanistic insights into its immunotoxicity in mutamouse","volume":"149","author":"Chepelev","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.clim.2019.01.006_bb0255","first-page":"246","article-title":"DAMPs ramp up drug toxicity","volume":"119","author":"Maher","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2019.01.006_bb0260","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1385\/IR:32:1-3:085","article-title":"JL, Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis","volume":"32","author":"Cross","year":"2005","journal-title":"Immunol. Res."},{"key":"10.1016\/j.clim.2019.01.006_bb0265","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1011031014433","article-title":"Immune responses against the myelin\/oligodendrocyte glycoprotein in experimental autoimmune demyelination","volume":"21","author":"von B\u00fcdingen","year":"2001","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0270","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3390\/ijms18102048","article-title":"Deciphering the role of B cells in multiple sclerosis-towards specific targeting of pathogenic function","volume":"18","author":"Lehmann-Horn","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2019.01.006_bb0275","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1471-4159.1997.69010214.x","article-title":"Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin","volume":"69","author":"Menon","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.clim.2019.01.006_bb0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2017.09.002","article-title":"Myelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model","volume":"86","author":"Khare","year":"2018","journal-title":"J. Autoimmunity"},{"key":"10.1016\/j.clim.2019.01.006_bb0285","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mcn.2016.05.001","article-title":"ROCK inhibitor abolishes the antibody response in experimental autoimmune myasthenia gravis","volume":"74","author":"Li","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.clim.2019.01.006_bb0290","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10735-018-9786-z","article-title":"Microglia polarization by methylprednizolone acetate accelerates cuprizone induced demyelination","volume":"49","author":"Noorzehi","year":"2018","journal-title":"J. Mol. Histol."},{"key":"10.1016\/j.clim.2019.01.006_bb0295","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0165-5728(98)00168-4","article-title":"Microglial\/macrophage accumulation during cuprizone-induced demyelination in C57BL\/6 mice","volume":"92","author":"Hiremath","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40478-018-0510-8","article-title":"Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945","volume":"6","author":"Beckmann","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.clim.2019.01.006_bb0305","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.4397","article-title":"Microglia emerge as central players in brain disease","volume":"23","author":"Salter","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2019.01.006_bb0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jnr.21841","article-title":"Brain-derived neurotrophic factor effects on oligodendrocyte progenitors of the basal forebrain are mediated through trkB and the MAP kinase pathway","volume":"87","author":"Van't Veer","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.clim.2019.01.006_bb0315","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1523\/JNEUROSCI.6595-10.2011","article-title":"Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion","volume":"31","author":"VonDran","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clim.2019.01.006_bb0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jneuroim.2005.07.001","article-title":"Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate","volume":"167","author":"Azoulay","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0325","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neulet.2009.05.057","article-title":"Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse","volume":"460","author":"Frota","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.clim.2019.01.006_bb0330","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0165-5728(02)00319-3","article-title":"Brain-derived neurotrophic factor in patients with multiple sclerosis","volume":"132","author":"Sarchielli","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2019.01.006_bb0335","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1352458506070146","article-title":"Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins","volume":"13","author":"Sarchielli","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2019.01.006_bb0340","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clim.2005.09.005","article-title":"Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy","volume":"118","author":"Caggiula","year":"2006","journal-title":"Clin. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.clim.2020.108460","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"record-id":"23478"},{"DOI":"10.1016\/j.clim.2020.108460","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000}},{"DOI":"10.1016\/j.clim.2019.01.006","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000}}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:57:45Z","timestamp":1761494265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618304625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":68,"alternative-id":["S1521661618304625"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.01.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Hydroxyfasudil alleviates demyelination through the inhibition of MOG antibody and microglia activation in cuprizone mouse model","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}